Hisyopathegenesis of nodular scleritis and diff between scleritis and episcleritis

Reading File
Finding Sources
Finding Sources
Searching Images

nodular scleritis episcleritis eye clinical

This composite educational image features a color photograph and corresponding Anterior Segment Optical Coherence Tomography (AS-OCT) scans of a right eye, illustrating clinical signs of nodular episcleritis and scleritis. The color photograph reveals marked violaceous ocular injection, superficial blood vessel congestion, and a localized nodular thickening approximately 4mm from the limbus. AS-OCT cross-sections (a) and (b) provide detailed visualization of the underlying tissue architecture. Key findings include nodular episcleral thickening (asterisk), a subepiscleral fluid level presenting as a hyporeflective space (black arrow), and intlamellar scleral edema (white arrow/asterisk). These OCT features correlate with the clinical appearance of vessel dilation and deep tissue inflammation. The image serves as a diagnostic reference for identifying inflammatory eye conditions using both external photography and non-invasive cross-sectional imaging, highlighting the relationship between visible clinical signs and internal structural alterations like scleral lamellae bisection by hyporeflective fluid.

This composite educational image features a color photograph and corresponding Anterior Segment Optical Coherence Tomography (AS-OCT) scans of a right eye, illustrating clinical signs of nodular episcleritis and scleritis. The color photograph reveals marked violaceous ocular injection, superficial blood vessel congestion, and a localized nodular thickening approximately 4mm from the limbus. AS-OCT cross-sections (a) and (b) provide detailed visualization of the underlying tissue architecture. Key findings include nodular episcleral thickening (asterisk), a subepiscleral fluid level presenting as a hyporeflective space (black arrow), and intlamellar scleral edema (white arrow/asterisk). These OCT features correlate with the clinical appearance of vessel dilation and deep tissue inflammation. The image serves as a diagnostic reference for identifying inflammatory eye conditions using both external photography and non-invasive cross-sectional imaging, highlighting the relationship between visible clinical signs and internal structural alterations like scleral lamellae bisection by hyporeflective fluid.

This clinical comparison chart consists of two side-by-side slit-lamp photographs (labeled A and B) documenting the progression and resolution of nodular anterior scleritis in a patient's left eye. Image A shows the eye one week after starting systemic treatment, demonstrating a distinct, elevated scleral nodule characterized by a deep purplish/violaceous hue. There is significant overlying episcleral and conjunctival vascular injection, with engorged, tortuous vessels radiating from the inflammatory site. Image B depicts the same eye three weeks after treatment initiation, illustrating a notable clinical improvement. The purplish hue has significantly faded, the nodular elevation has flattened, and there is a visible reduction in vascular engorgement and perilimbal hyperemia. This comparison serves as a clinical timeline for the response of scleritis associated with Behçet’s disease to immunosuppressive and corticosteroid therapy. The visual features highlighted are critical for differentiating nodular scleritis from simpler episcleritis, specifically the characteristic 'bluish' tint visible in natural light indicating deep scleral involvement.

This clinical comparison chart consists of two side-by-side slit-lamp photographs (labeled A and B) documenting the progression and resolution of nodular anterior scleritis in a patient's left eye. Image A shows the eye one week after starting systemic treatment, demonstrating a distinct, elevated scleral nodule characterized by a deep purplish/violaceous hue. There is significant overlying episcleral and conjunctival vascular injection, with engorged, tortuous vessels radiating from the inflammatory site. Image B depicts the same eye three weeks after treatment initiation, illustrating a notable clinical improvement. The purplish hue has significantly faded, the nodular elevation has flattened, and there is a visible reduction in vascular engorgement and perilimbal hyperemia. This comparison serves as a clinical timeline for the response of scleritis associated with Behçet’s disease to immunosuppressive and corticosteroid therapy. The visual features highlighted are critical for differentiating nodular scleritis from simpler episcleritis, specifically the characteristic 'bluish' tint visible in natural light indicating deep scleral involvement.

A longitudinal comparison series showing the clinical progression of tuberculous nodular episcleritis and anterior scleritis in the right eye. The image is structured into three temporal stages (a, b, c), each paired with a slit-lamp photograph and a corresponding anterior segment optical coherence tomography (AS-OCT) scan. Stage (a) displays intense superotemporal sector hyperaemia, a subconjunctival nodule, and violaceous injection; AS-OCT reveals a hyperreflective episcleral nodule (asterisk) and hyporeflective spaces indicating subepiscleral (arrow) and scleral (arrowhead) oedema. Stage (b), following initiation of antituberculous chemotherapy, demonstrates reduced hyperaemia and clinical resolution of the nodule, though AS-OCT shows persistent hyporeflective intrascleral spaces (arrow) and subepiscleral oedema (arrowhead). Stage (c), upon completion of therapy, shows total clinical remission with no hyperaemia and a restored, healthy anatomical structure on AS-OCT with complete elimination of prior lesions. This comparison illustrates the utility of AS-OCT in monitoring deep tissue resolution of inflammatory eye disease that may persist after superficial clinical signs have improved.

A longitudinal comparison series showing the clinical progression of tuberculous nodular episcleritis and anterior scleritis in the right eye. The image is structured into three temporal stages (a, b, c), each paired with a slit-lamp photograph and a corresponding anterior segment optical coherence tomography (AS-OCT) scan. Stage (a) displays intense superotemporal sector hyperaemia, a subconjunctival nodule, and violaceous injection; AS-OCT reveals a hyperreflective episcleral nodule (asterisk) and hyporeflective spaces indicating subepiscleral (arrow) and scleral (arrowhead) oedema. Stage (b), following initiation of antituberculous chemotherapy, demonstrates reduced hyperaemia and clinical resolution of the nodule, though AS-OCT shows persistent hyporeflective intrascleral spaces (arrow) and subepiscleral oedema (arrowhead). Stage (c), upon completion of therapy, shows total clinical remission with no hyperaemia and a restored, healthy anatomical structure on AS-OCT with complete elimination of prior lesions. This comparison illustrates the utility of AS-OCT in monitoring deep tissue resolution of inflammatory eye disease that may persist after superficial clinical signs have improved.

Content Type: Clinical Photograph. This composite image shows two views of a patient's right eye, highlighting inflammatory ocular signs. The left panel shows a frontal view of the eye with significant violaceous (purplish) scleral hyperemia and a distinct, circumscribed nodule (circled) on the temporal sclera. The right panel provides a lateral view, further illustrating the elevation and localized nature of the nodular lesion against the hyperemic scleral background. The purplish hue is characteristic of deep episcleral or scleral vessel involvement, often seen in scleritis. The iris appears brown and the cornea remains clear in these views. The images demonstrate the clinical presentation of nodular scleritis, an inflammatory condition of the eye's outer protective layer. These findings are pedagogically useful for distinguishing between superficial episcleritis (which typically presents with a brighter red hue) and deeper scleral inflammation (which exhibits a darker, violaceous color).

Content Type: Clinical Photograph. This composite image shows two views of a patient's right eye, highlighting inflammatory ocular signs. The left panel shows a frontal view of the eye with significant violaceous (purplish) scleral hyperemia and a distinct, circumscribed nodule (circled) on the temporal sclera. The right panel provides a lateral view, further illustrating the elevation and localized nature of the nodular lesion against the hyperemic scleral background. The purplish hue is characteristic of deep episcleral or scleral vessel involvement, often seen in scleritis. The iris appears brown and the cornea remains clear in these views. The images demonstrate the clinical presentation of nodular scleritis, an inflammatory condition of the eye's outer protective layer. These findings are pedagogically useful for distinguishing between superficial episcleritis (which typically presents with a brighter red hue) and deeper scleral inflammation (which exhibits a darker, violaceous color).

This clinical photograph, captured via slit-lamp biomicroscopy, illustrates a focal scleral nodule in a patient with systemic sarcoidosis. The image focuses on the anterior segment of the eye, specifically the bulbar conjunctiva and underlying sclera. The primary feature is a well-circumscribed, elevated, pinkish-red nodular mass. Surrounding the lesion is intense episcleral and conjunctival injection, characterized by dilated, tortuous blood vessels radiating towards the nodule, indicating significant localized inflammation and vascular engorgement. The central portion of the nodule appears slightly paler than its hyperemic periphery. This finding represents a rare ocular manifestation of sarcoidosis, showcasing granulomatous infiltration of the sclera. Key educational concepts include the identification of inflammatory scleral lesions, differentiating episcleritis from nodular scleritis, and recognizing ocular markers of systemic granulomatous diseases. The image is a valuable diagnostic reference for ophthalmologists and rheumatologists managing multi-system inflammatory conditions.

This clinical photograph, captured via slit-lamp biomicroscopy, illustrates a focal scleral nodule in a patient with systemic sarcoidosis. The image focuses on the anterior segment of the eye, specifically the bulbar conjunctiva and underlying sclera. The primary feature is a well-circumscribed, elevated, pinkish-red nodular mass. Surrounding the lesion is intense episcleral and conjunctival injection, characterized by dilated, tortuous blood vessels radiating towards the nodule, indicating significant localized inflammation and vascular engorgement. The central portion of the nodule appears slightly paler than its hyperemic periphery. This finding represents a rare ocular manifestation of sarcoidosis, showcasing granulomatous infiltration of the sclera. Key educational concepts include the identification of inflammatory scleral lesions, differentiating episcleritis from nodular scleritis, and recognizing ocular markers of systemic granulomatous diseases. The image is a valuable diagnostic reference for ophthalmologists and rheumatologists managing multi-system inflammatory conditions.

This composite medical image provides a multi-modal clinical and diagnostic evaluation of ocular scleral nodules. Panels A and B are clinical photographs of a right eye showing two distinct, raised, round scleral nodules located in the superior and inferior bulbar regions. The nodules are well-circumscribed and characterized by prominent, dilated episcleral 'feeder' vessels crossing their surfaces, while the surrounding conjunctiva remains relatively white and non-inflamed. Panel C presents an Ultrasound Biomicroscopy (UBM) cross-sectional image of a nodule. The UBM reveals a homogenous, hypo-reflective subconjunctival mass. Notably, the imaging demonstrates localized scleral thinning (scleral melting) beneath the lesion, without evidence of full-thickness perforation. These findings are clinically relevant for the differential diagnosis of infectious scleritis, particularly rare manifestations like Tropheryma whipplei, or inflammatory conditions such as nodular episcleritis. The images serve as an educational resource for identifying ocular mass lesions and the utility of UBM in assessing scleral integrity.

This composite medical image provides a multi-modal clinical and diagnostic evaluation of ocular scleral nodules. Panels A and B are clinical photographs of a right eye showing two distinct, raised, round scleral nodules located in the superior and inferior bulbar regions. The nodules are well-circumscribed and characterized by prominent, dilated episcleral 'feeder' vessels crossing their surfaces, while the surrounding conjunctiva remains relatively white and non-inflamed. Panel C presents an Ultrasound Biomicroscopy (UBM) cross-sectional image of a nodule. The UBM reveals a homogenous, hypo-reflective subconjunctival mass. Notably, the imaging demonstrates localized scleral thinning (scleral melting) beneath the lesion, without evidence of full-thickness perforation. These findings are clinically relevant for the differential diagnosis of infectious scleritis, particularly rare manifestations like Tropheryma whipplei, or inflammatory conditions such as nodular episcleritis. The images serve as an educational resource for identifying ocular mass lesions and the utility of UBM in assessing scleral integrity.

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
I have all the information I need. Let me now compile a comprehensive answer.

Histopathogenesis of Nodular Scleritis & Comparison with Episcleritis


Anatomy Primer (foundation for understanding pathogenesis)

The anterior sclera has three pre-equatorial vascular layers (Kanski's):
  • Conjunctival vessels - most superficial, tortuous arteries/straight veins
  • Superficial episcleral plexus - straight, radially configured; congested in episcleritis
  • Deep vascular plexus - within superficial scleral stroma; congested in scleritis (gives the characteristic violaceous/purplish hue)
Diagram showing episcleritis vascular congestion in superficial episcleral plexus (A) vs. scleritis congestion in deep vascular plexus (B)
Fig. 9.1 (Kanski) - Episcleritis with maximal congestion of superficial episcleral plexus (A); Scleritis with scleral thickening and maximal deep vascular plexus congestion (B)

Histopathogenesis of Nodular Scleritis

Classification Context

Scleritis is classified as:
TypeNotes
Anterior Non-necrotizingDiffuse or Nodular
Anterior Necrotizing with inflammationMost destructive
Anterior Necrotizing without inflammation (Scleromalacia perforans)Silent, RA-related
Posterior scleritisPosterior to rectus insertions
Nodular anterior scleritis has an incidence equal to diffuse anterior scleritis. A disproportionately large number of those with nodular disease have a prior history of herpes zoster ophthalmicus.

Histopathogenesis - Step by Step

1. Immune trigger Scleritis is an immune-mediated (or occasionally infectious) process. The deep scleral vascular plexus becomes involved, unlike in episcleritis. In ~50% of cases it accompanies a systemic inflammatory disease (RA most common, then ANCA-associated vasculitis, SLE, IBD, relapsing polychondritis, gout). The 10% infectious sub-group features organisms like VZV, HSV, syphilis, TB, and Pseudomonas. - Kanski's Clinical Ophthalmology 10th ed.
2. Zonal granulomatous necrosis (central mechanism) The hallmark histology of nodular and necrotizing scleritis is a zonal pattern of inflammation:
  • Central area of collagen necrosis (fibrinoid necrosis of scleral collagen bundles)
  • Surrounded by palisading epithelioid histiocytes and giant cells (granulomatous reaction)
  • Peripheral zone of lymphocytes and plasma cells
  • Vascular occlusion and ischaemia contribute to collagen destruction This zonal pattern resembles the rheumatoid nodule, and in RA-associated scleritis the pathogenesis mirrors the rheumatoid granuloma - immune complex deposition -> complement activation -> vasculitis -> tissue necrosis. - Kanski's; Rheumatology 2-Volume Set (Elsevier 2022)
3. Nodule formation in nodular scleritis specifically
  • Oedema and inflammatory cell infiltration involve the full thickness of the sclera but are localized, producing a discrete, elevated, tender nodule
  • The nodule has a deeper blue-red colour than episcleral nodules (because the deep plexus is involved)
  • On slit-lamp examination, the anterior scleral surface is elevated (vs. episcleritis where the scleral surface is flat)
  • Nodules are immobile - they cannot be displaced over the underlying sclera (unlike episcleral nodules)
  • Most frequently develop in the interpalpebral region close to the limbus
  • Instillation of 10% phenylephrine blanches conjunctival and superficial episcleral vessels but NOT the deep plexus overlying the nodule
4. Progression risk
  • Multiple nodules may expand and coalesce if treatment is delayed
  • As inflammation subsides, increased scleral translucency (grey/bluish appearance) develops - due to rearrangement of collagen fibers
  • More than 10% of nodular scleritis cases progress to necrotizing disease; if treated early, superficial necrosis does not occur and the nodule heals centrally leaving a small atrophic scar

Clinical Images of Nodular Scleritis

Nodular scleritis - violaceous ocular injection with localized nodular thickening, AS-OCT showing episcleral nodule and subepiscleral fluid
AS-OCT cross-sections showing nodular episcleral thickening (asterisk), subepiscleral fluid (hyporeflective space, black arrow), and intralamellar scleral oedema (white arrow) - characteristic of nodular scleritis
Nodular anterior scleritis - scleral nodule with purplish violaceous hue and engorged tortuous vessels
Nodular anterior scleritis: temporal scleral nodule with characteristic purplish hue and dilated vessels

Comparison: Scleritis vs. Episcleritis

FeatureEpiscleritisScleritis
Layer involvedEpisclera (superficial connective tissue layer between scleral stroma and Tenon capsule)Full thickness of sclera + deep vascular plexus
Vascular plexusSuperficial episcleral plexus (congested)Deep vascular plexus (congested)
ColorBright/salmon pink, peri-limbal injectionDeeper violaceous/purple hue - best seen in daylight
PainMild discomfort or absent (up to 50% painless); grittinessSevere boring/gnawing pain, often wakes patient at night; radiates to temple/face; responds poorly to common analgesics
Phenylephrine test10% phenylephrine blanches vessels (positive blanch)10% phenylephrine does NOT blanch deep scleral vessels (negative blanch)
Slit-lamp surfaceFlat anterior scleral surfaceElevated anterior scleral surface (scleral oedema)
Nodule mobilityEpiscleral nodule is movable over scleraScleral nodule is immovable
Vision threatNOT vision-threateningCan threaten vision (glaucoma, peripheral keratitis, uveitis, scleral perforation)
Systemic associationRare (majority idiopathic)~50% associated with systemic disease (RA, ANCA vasculitis, SLE, gout, IBD)
Cotton swab testVessels move with conjunctivaVessels do NOT move with conjunctiva
BilateralityOften bilateral (>50%)Bilateral in 60% for necrotizing; variable for others
CourseSelf-limiting (days to 3 weeks), recurrent but benignRequires systemic therapy; mean duration ~6 years; can progress
HistopathologyNon-specific vascular dilation + mild perivascular lymphocytic infiltrateZonal granulomatous necrosis, fibrinoid collagen necrosis, epithelioid histiocytes, palisading giant cells, vasculitis
Scleral thinningDoes NOT occurCan occur - choroidal show/bulge in severe cases
IOPRarely elevatedGlaucoma is the most common cause of visual loss
TreatmentCool compresses; topical NSAIDs or mild topical steroids; oral NSAIDs rarely neededSystemic NSAIDs (flurbiprofen, indomethacin) first-line; systemic corticosteroids; immunosuppressives (methotrexate, azathioprine); biologics for refractory cases
Sources: Kanski's Clinical Ophthalmology 10th Ed., Wills Eye Manual, Rosen's Emergency Medicine, Rheumatology 2-Vol Set (Elsevier 2022)

Key Memory Tricks

  • "Epi" = superficial - episclera only, salmon pink, blanches, self-limits
  • "Sclera" = deep - violaceous, doesn't blanch, painful at night, systemic disease, vision threat
  • Nodular scleritis vs. nodular episcleritis: immovable + elevated scleral surface + blue-red colour = scleritis; movable + flat scleral surface + pink = episcleritis
  • The phenylephrine test is the single most useful bedside test to distinguish the two

?

Could you clarify what you'd like? For example:
  • Did something in my previous answer need more explanation?
  • Do you have a new question?
  • Was there a typo or incomplete message?

Got no answer for previous question

I did provide a full, detailed answer to your question on Histopathogenesis of Nodular Scleritis and Difference between Scleritis and Episcleritis. It may not have rendered properly on your end. Here is the complete answer again:

Histopathogenesis of Nodular Scleritis

Anatomy Foundation

The anterior sclera has three pre-equatorial vascular layers:
  • Conjunctival vessels - most superficial
  • Superficial episcleral plexus - straight, radially configured; congested in episcleritis
  • Deep vascular plexus - within superficial scleral stroma; congested in scleritis (gives the violaceous/purple hue)

Pathogenesis - Step by Step

1. Immune trigger Scleritis is primarily an immune-mediated condition involving the deep scleral vascular plexus. In ~50% of cases it is associated with a systemic inflammatory disease - most commonly rheumatoid arthritis, followed by ANCA-associated vasculitis (GPA), SLE, IBD, relapsing polychondritis, and gout. About 10% of cases are infectious (VZV, syphilis, TB, Pseudomonas).
2. Zonal granulomatous necrosis (the key histological pattern)
  • Central zone of fibrinoid necrosis of scleral collagen
  • Surrounded by palisading epithelioid histiocytes and giant cells
  • Peripheral zone of lymphocytes and plasma cells
  • Vasculitis and vascular occlusion cause ischaemia, amplifying collagen destruction
  • This mirrors the rheumatoid nodule histologically - immune complex deposition → complement activation → vasculitis → tissue necrosis
3. Nodule formation (specific to nodular type)
  • Inflammation is localized but involves the full thickness of the sclera
  • Produces a discrete, elevated, immovable tender nodule
  • Characteristically deep blue-red in colour (because the deep plexus is involved)
  • Slit-lamp shows an elevated anterior scleral surface (distinguishes it from episcleritis nodule where the surface is flat)
  • Most commonly in the interpalpebral region, close to the limbus
  • 10% phenylephrine blanches superficial/episcleral vessels but does NOT blanch the deep vessels overlying the nodule
4. Progression
  • Nodules expand and coalesce if untreated
  • As inflammation resolves, scleral translucency increases (grey-blue sclera) due to collagen fiber rearrangement
  • >10% progress to necrotizing scleritis if untreated
  • With early treatment, the nodule heals from the centre leaving a small atrophic scar

Clinical Images

Nodular scleritis with violaceous injection, localized nodular thickening, and AS-OCT showing episcleral nodule, subepiscleral fluid, and intralamellar scleral oedema
Nodular anterior scleritis - temporal scleral nodule with characteristic purplish violaceous hue and engorged tortuous vessels

Difference: Scleritis vs. Episcleritis

FeatureEpiscleritisScleritis
Layer involvedEpisclera only (superficial)Full thickness sclera + deep vascular plexus
ColourSalmon pink, bright redDeep violaceous/purple (best seen in daylight)
PainMild or absent (50% painless); grittinessSevere boring pain, wakes at night, radiates to face/temple, poorly controlled by analgesics
Phenylephrine 10% testVessels blanch (positive)Vessels do NOT blanch (negative)
Slit-lamp surfaceFlat scleral surfaceElevated scleral surface (scleral oedema)
Nodule mobilityEpiscleral nodule - movable over scleraScleral nodule - immovable
Cotton swab testVessels move with conjunctivaVessels do NOT move with conjunctiva
Vision threatNOT vision-threateningYES - glaucoma, keratitis, uveitis, scleral thinning
Systemic associationMajority idiopathic~50% with systemic disease (RA, vasculitis, SLE, gout)
HistologyMild perivascular lymphocytic infiltrate, vascular dilationZonal granulomatous necrosis, fibrinoid collagen necrosis, palisading histiocytes/giant cells, vasculitis
Scleral thinningDoes NOT occurOccurs in severe/necrotizing cases (choroidal show)
IOPRarely elevatedGlaucoma = most common cause of visual loss
CourseSelf-limiting (days-3 weeks), recurrent but benignRequires systemic therapy; mean duration ~6 years
TreatmentTopical NSAIDs/mild steroids; oral NSAIDs occasionallySystemic NSAIDs (flurbiprofen, indomethacin); oral corticosteroids; immunosuppressives; biologics for refractory cases

Key Memory Points

  • Phenylephrine test is the single most useful bedside distinguishing test
  • Colour: pink = episcleritis (superficial); purple/violet = scleritis (deep)
  • Nodule: movable + flat scleral surface = episcleral; immovable + elevated surface = scleral
  • Pain at night strongly suggests scleritis
  • Episcleritis = benign, self-limiting, rarely systemic; Scleritis = serious, vision-threatening, systemic association in 50%
Sources: Kanski's Clinical Ophthalmology 10th Ed.; Wills Eye Manual; Rosen's Emergency Medicine; Rheumatology 2-Volume Set (Elsevier 2022)
This is a shared conversation. Sign in to Orris to start your own chat.